These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 7518301

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat.
    Männistö PT, Tuomainen P, Tuominen RK.
    Br J Pharmacol; 1992 Mar; 105(3):569-74. PubMed ID: 1628144
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effects of catechol-O-methyltransferase inhibitors and L-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum.
    Kaakkola S, Wurtman RJ.
    J Neurochem; 1993 Jan; 60(1):137-44. PubMed ID: 8417137
    [Abstract] [Full Text] [Related]

  • 6. Peripheral and central inhibitors of catechol-O-methyl transferase: effects on liver and brain COMT activity and L-DOPA metabolism.
    Brannan T, Prikhojan A, Yahr MD.
    J Neural Transm (Vienna); 1997 Jan; 104(1):77-87. PubMed ID: 9085195
    [Abstract] [Full Text] [Related]

  • 7. Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats.
    Napolitano A, Zürcher G, Da Prada M.
    Eur J Pharmacol; 1995 Feb 06; 273(3):215-21. PubMed ID: 7737328
    [Abstract] [Full Text] [Related]

  • 8. Effects of three types of catechol O-methylation inhibitors on L-3,4-dihydroxyphenylalanine-induced circling behaviour in rats.
    Törnwall M, Männistö PT.
    Eur J Pharmacol; 1993 Nov 30; 250(1):77-84. PubMed ID: 8119326
    [Abstract] [Full Text] [Related]

  • 9. The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers.
    Keränen T, Gordin A, Harjola VP, Karlsson M, Korpela K, Pentikäinen PJ, Rita H, Seppälä L, Wikberg T.
    Clin Neuropharmacol; 1993 Apr 30; 16(2):145-56. PubMed ID: 8477410
    [Abstract] [Full Text] [Related]

  • 10. The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats.
    Gerlach M, Xiao AY, Kuhn W, Lehnfeld R, Waldmeier P, Sontag KH, Riederer P.
    J Neural Transm (Vienna); 2001 Apr 30; 108(2):189-204. PubMed ID: 11314772
    [Abstract] [Full Text] [Related]

  • 11. Microdialysis with radiometric monitoring of L-[β-11C]DOPA to assess dopaminergic metabolism: effect of inhibitors of L-amino acid decarboxylase, monoamine oxidase, and catechol-O-methyltransferase on rat striatal dialysate.
    Okada M, Nakao R, Hosoi R, Zhang MR, Fukumura T, Suzuki K, Inoue O.
    J Cereb Blood Flow Metab; 2011 Jan 30; 31(1):124-31. PubMed ID: 20407462
    [Abstract] [Full Text] [Related]

  • 12. Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats.
    Napolitano A, Bellini G, Borroni E, Zürcher G, Bonuccelli U.
    Parkinsonism Relat Disord; 2003 Jan 30; 9(3):145-50. PubMed ID: 12573869
    [Abstract] [Full Text] [Related]

  • 13. Effect of intracerebral 6-nitronoradrenaline, an endogenous catechol-O-methyltransferase (COMT) inhibitor, on striatal dopamine metabolism in anaesthetised rats.
    Huotari M, Passlin M, Nordberg HL, Forsberg M, Kotisaari S, Tuomisto L, Shintani F, Tanaka KF, Reenilä I, Laitinen K, Männistö PT.
    J Neurosci Methods; 2001 Aug 15; 109(1):47-52. PubMed ID: 11489299
    [Abstract] [Full Text] [Related]

  • 14. Different renal effects of two inhibitors of catechol-O-methylation in the rat: entacapone and CGP 28014.
    Hansell P, Odlind C, Männistö PT.
    Acta Physiol Scand; 1998 Apr 15; 162(4):489-94. PubMed ID: 9597116
    [Abstract] [Full Text] [Related]

  • 15. Effects of CGP 28014 on the in vivo release and metabolism of dopamine in the rat striatum assessed by brain microdialysis.
    Steulet AF, Stöcklin K, Wicki P, Waldmeier P.
    Neurochem Res; 1993 Nov 15; 18(11):1131-6. PubMed ID: 8255364
    [Abstract] [Full Text] [Related]

  • 16. The central aromatic amino acid DOPA decarboxylase inhibitor, NSD-1015, does not inhibit L-DOPA-induced circling in unilateral 6-OHDA-lesioned-rats.
    Treseder SA, Rose S, Jenner P.
    Eur J Neurosci; 2001 Jan 15; 13(1):162-70. PubMed ID: 11135014
    [Abstract] [Full Text] [Related]

  • 17. BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation.
    Parada A, Loureiro AI, Vieira-Coelho MA, Hainzl D, Soares-da-Silva P.
    Eur J Pharmacol; 2001 May 18; 420(1):27-32. PubMed ID: 11412836
    [Abstract] [Full Text] [Related]

  • 18. CGP 28014, a new inhibitor of cerebral catechol-O-methylation with a non-catechol structure.
    Waldmeier PC, Baumann PA, Feldtrauer JJ, Hauser K, Bittiger H, Bischoff S, von Sprecher G.
    Naunyn Schmiedebergs Arch Pharmacol; 1990 Sep 18; 342(3):305-11. PubMed ID: 1980718
    [Abstract] [Full Text] [Related]

  • 19. Effect of the new selective COMT inhibitor CGP 28014 A on the formation of 3-O-methyldopa (3OMD) in plasma of healthy subjects.
    Bieck PR, Nilsson E, Antonin KH.
    J Neural Transm Suppl; 1990 Sep 18; 32():387-91. PubMed ID: 2128511
    [Abstract] [Full Text] [Related]

  • 20. Effect of high single doses of levodopa and carbidopa on brain dopamine and its metabolites: modulation by selective inhibitors of monoamine oxidase and/or catechol-O-methyltransferase in the male rat.
    Männistö PT, Tuomainen P.
    Naunyn Schmiedebergs Arch Pharmacol; 1991 Oct 18; 344(4):412-8. PubMed ID: 1766471
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.